Home » Stocks » VistaGen Therapeutics

VistaGen Therapeutics, Inc. (VTGN)

Stock Price: $0.785 USD -0.037 (-4.47%)
Updated Oct 23, 2020 4:00 PM EDT - Market closed
After-hours: $0.770 -0.014 (-1.80%) Oct 23, 7:35 PM

Stock Price Chart

Key Info

Market Cap 44.06M
Revenue (ttm) n/a
Net Income (ttm) -17.69M
Shares Out 56.16M
EPS (ttm) -0.41
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 23, 2020
Last Price $0.785
Previous Close $0.821
Change ($) -0.037
Change (%) -4.47%
Day's Open 0.821
Day's Range 0.766 - 0.821
Day's Volume 476,068
52-Week Range 0.294 - 1.430

More Stats

Market Cap 44.06M
Enterprise Value 47.03M
Earnings Date (est) Nov 5, 2020
Ex-Dividend Date n/a
Shares Outstanding 56.16M
Float 49.56M
EPS (basic) -0.42
EPS (diluted) -0.41
FCF / Share -0.25
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 2.51M
Short Ratio 3.35
Short % of Float 5.06%
Beta 0.29
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 26.54
Revenue n/a
Operating Income -17.70M
Net Income -17.69M
Free Cash Flow -13.80M
Net Cash -2.97M
Net Cash / Share -0.05
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -115.75%
ROE -653.72%
ROIC -313.40%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (3)

Buy 2
Overweight 0
Hold 1
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$4.50*
(473.61% upside)
Low
3.00
Current: $0.785
High
6.00
Target: 4.50
*Average 12-month price target from 2 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue---1.25---0.201.342.07
Revenue Growth--------85.07%-35.19%-
Gross Profit---1.25---0.201.342.07
Operating Income-20.80-24.56-14.20-10.25-17.85-6.78-5.03-6.79-9.04-6.56
Net Income-20.77-24.59-14.35-10.26-47.22-13.89-2.97-12.89-12.21-9.48
Shares Outstanding47.9628.5613.897.531.771.471.170.910.74-
Earnings Per Share-0.50-0.90-1.12-1.54-29.08-10.61-3.81-25.40-16.60-36.20
Operating Cash Flow-15.76-14.53-9.06-7.26-4.81-2.77-2.13-3.46-3.57-0.84
Capital Expenditures--0.17--0.24-0.03--0.01-0.14-0.03-0.06
Free Cash Flow-15.76-14.70-9.06-7.50-4.83-2.77-2.14-3.60-3.60-0.90
Cash & Equivalents1.3613.1010.382.920.430.07-0.640.080.14
Total Debt4.090.070.070.070.0714.266.925.353.5711.80
Net Cash / Debt-2.7413.0310.312.850.36-14.19-6.92-4.71-3.49-11.66
Assets5.7714.0111.283.710.990.270.260.880.340.32
Liabilities11.506.944.363.103.9720.8113.0613.446.0518.67
Book Value-5.737.086.920.62-2.98-20.54-12.80-12.56-5.71-32.88
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name VistaGen Therapeutics, Inc.
Country United States
Employees 9
CEO Shawn K. Singh

Stock Information

Ticker Symbol VTGN
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: VTGN

Description

VistaGen Therapeutics, a clinical-stage biopharmaceutical company, engages in developing and commercializing medicines to treat diseases and disorders of the central nervous system. It focuses on depressive and social anxiety disorders. The company's lead product candidate is AV-101 that is in Phase II clinical trial for the treatment of chronic neuropathic pain, epilepsy, major depressive disorder (MDD), parkinson's disease levodopa-induced dyskinesia, and suicidal ideation; PH94B, a neuroactive nasal spray that is in Phase III clinical trial for social anxiety disorder (SAD), and Phase IIa clinical trial for generalized anxiety disorder; and PH10, a neuroactive nasal spray that is in Phase IIb clinical trial for MDD. It has licensing, sublicensing, and collaboration agreements with Pherin Pharmaceuticals, Inc.; BlueRock Therapeutics, LP; and Cato Research Ltd. The company also has a strategic licensing and collaboration agreement with EverInsight Therapeutics Inc. for the clinical development and commercialization of PH94B for multiple anxiety-related disorders in Greater China, South Korea, and Southeast Asia. VistaGen Therapeutics, Inc. was founded in 1998 and is headquartered in South San Francisco, California.